Hildur Helgadottir

20PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsMortality
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 18, 2026
Polygenic Risk Scores and Its Association With Cutaneous Melanoma Risk in the Swedish Population.

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|Apr 24, 2026
The role of radiotherapy in patients with advanced melanoma failing targeted therapy.

|Dec 07, 2025
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.

Karl Björkström, Cissi Liu, Anna Fager

|Sep 10, 2025
Germline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.

Muyi Yang, Suzanne Egyhazi Brage, Jan Lapins

|Aug 25, 2025
POT1 genetic testing in melanoma-prone families in Sweden: germline variant prevalence and tumor spectrum in identified carriers.

Konstantinos Papadakis, Francesca Portelli, Karina Schultz

Pageof 4

Frequent Collaborators

5 joint publications

Lars Ny

5 joint publications

Jan Lapins

3 joint publications

Karina Schultz

3 joint publications

Roger Olofsson Bagge